BR112019003479A2 - formulação e composição farmacêuticas, recipiente vedado, dispositivo de administração subcutânea, kit, forma de dosagem unitária farmacêutica, e, método para tratamento de um indivíduo sofrendo de uma doença ou de um distúrbio associados ao complemento dependente de masp-2. - Google Patents
formulação e composição farmacêuticas, recipiente vedado, dispositivo de administração subcutânea, kit, forma de dosagem unitária farmacêutica, e, método para tratamento de um indivíduo sofrendo de uma doença ou de um distúrbio associados ao complemento dependente de masp-2.Info
- Publication number
- BR112019003479A2 BR112019003479A2 BR112019003479-0A BR112019003479A BR112019003479A2 BR 112019003479 A2 BR112019003479 A2 BR 112019003479A2 BR 112019003479 A BR112019003479 A BR 112019003479A BR 112019003479 A2 BR112019003479 A2 BR 112019003479A2
- Authority
- BR
- Brazil
- Prior art keywords
- masp
- disorder
- kit
- treating
- composition
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000007920 subcutaneous administration Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a formulações estáveis, de alta concentração e baixa viscosidade de anticorpos inibitórios de masp-2, a kits compreendendo as formulações e a métodos terapêuticos usando as formulações e kits para a inibição dos efeitos adversos da ativação de complemento dependente de masp-2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662382156P | 2016-08-31 | 2016-08-31 | |
US62/382,156 | 2016-08-31 | ||
PCT/US2017/049415 WO2018045054A1 (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003479A2 true BR112019003479A2 (pt) | 2019-05-21 |
Family
ID=61301617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003479-0A BR112019003479A2 (pt) | 2016-08-31 | 2017-08-30 | formulação e composição farmacêuticas, recipiente vedado, dispositivo de administração subcutânea, kit, forma de dosagem unitária farmacêutica, e, método para tratamento de um indivíduo sofrendo de uma doença ou de um distúrbio associados ao complemento dependente de masp-2. |
Country Status (29)
Country | Link |
---|---|
US (2) | US11628217B2 (pt) |
EP (1) | EP3506886B1 (pt) |
JP (2) | JP6864747B2 (pt) |
KR (2) | KR102444154B1 (pt) |
CN (3) | CN116327695A (pt) |
AR (1) | AR109494A1 (pt) |
AU (2) | AU2017321605B2 (pt) |
BR (1) | BR112019003479A2 (pt) |
CA (1) | CA3035252C (pt) |
CL (1) | CL2019000508A1 (pt) |
CO (1) | CO2019002239A2 (pt) |
CR (1) | CR20190150A (pt) |
CU (1) | CU20190015A7 (pt) |
EA (1) | EA201990598A1 (pt) |
EC (1) | ECSP19021312A (pt) |
GE (1) | GEP20217252B (pt) |
IL (1) | IL265071B2 (pt) |
JO (1) | JOP20170170B1 (pt) |
MA (1) | MA46109A (pt) |
MX (2) | MX2019002338A (pt) |
MY (1) | MY189411A (pt) |
PE (1) | PE20190469A1 (pt) |
PH (1) | PH12019500365A1 (pt) |
SG (2) | SG11201901444PA (pt) |
TW (2) | TWI730310B (pt) |
UA (1) | UA122733C2 (pt) |
UY (1) | UY37391A (pt) |
WO (1) | WO2018045054A1 (pt) |
ZA (1) | ZA201901891B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102564616B1 (ko) * | 2016-01-05 | 2023-08-08 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
MA49960A (fr) * | 2017-08-25 | 2021-06-02 | Omeros Corp | Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
CA3159167A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
CN115052604A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
CA3159159A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
IL300245A (en) | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
WO2022087610A1 (en) * | 2020-10-22 | 2022-04-28 | Allakos Inc. | Anti-siglec-8 antibody formulations |
BR112023025596A2 (pt) * | 2021-06-08 | 2024-02-27 | Jiangxi Jemincare Group Co Ltd | Anticorpo anti-masp-2 e uso do mesmo |
WO2024118840A1 (en) | 2022-11-30 | 2024-06-06 | Omeros Corporation | Fused pyrimidines as masp-2 inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
AU2006330858A1 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
CN102781471B (zh) | 2009-10-16 | 2016-10-12 | 奥默罗斯公司 | 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法 |
US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
RU2662563C2 (ru) | 2011-04-08 | 2018-07-26 | Юниверсити Оф Лестер | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PE20141672A1 (es) * | 2011-05-02 | 2014-11-26 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 |
MX347691B (es) | 2011-05-04 | 2017-05-09 | Omeros Corp | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
NZ629473A (en) | 2012-06-18 | 2017-02-24 | Univ Leicester | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
HUE051746T2 (hu) * | 2013-10-17 | 2021-03-29 | Omeros Corp | Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére |
WO2016034648A1 (en) * | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
US20180000932A1 (en) | 2014-12-31 | 2018-01-04 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
EP3373963A4 (en) | 2015-11-09 | 2019-07-10 | Omeros Corporation | METHODS OF TREATING SUFFERING RELATED TO MASP-2-DEPENDENT COMPLEMENTAL ACTIVATION |
KR102564616B1 (ko) | 2016-01-05 | 2023-08-08 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
CA3096270C (en) | 2016-03-31 | 2024-05-21 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/ar active
- 2017-08-29 TW TW108111015A patent/TWI730310B/zh active
- 2017-08-29 TW TW106129287A patent/TWI719245B/zh active
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/ja active Active
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/ko active IP Right Grant
- 2017-08-30 BR BR112019003479-0A patent/BR112019003479A2/pt active Search and Examination
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/ko not_active IP Right Cessation
- 2017-08-30 MA MA046109A patent/MA46109A/fr unknown
- 2017-08-30 EA EA201990598A patent/EA201990598A1/ru unknown
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en active Application Filing
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/zh active Pending
- 2017-08-30 CR CR20190150A patent/CR20190150A/es unknown
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/es unknown
- 2017-08-30 UA UAA201903034A patent/UA122733C2/uk unknown
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/es unknown
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/zh active Pending
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/zh active Active
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/es unknown
- 2017-08-31 UY UY0001037391A patent/UY37391A/es unknown
- 2017-08-31 AR ARP170102432A patent/AR109494A1/es unknown
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/es unknown
- 2019-02-26 MX MX2023014120A patent/MX2023014120A/es unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/es unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/es unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/ja active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019003479A2 (pt) | formulação e composição farmacêuticas, recipiente vedado, dispositivo de administração subcutânea, kit, forma de dosagem unitária farmacêutica, e, método para tratamento de um indivíduo sofrendo de uma doença ou de um distúrbio associados ao complemento dependente de masp-2. | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
MX2022003572A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
BR112018010018A2 (pt) | moduladores de ror-gama | |
BR112017014994A2 (pt) | formulação em pó nasal para o tratamento de hipoglicemia | |
EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto | |
MX2022000712A (es) | Moduladores de nlrp3. | |
EA201990399A1 (ru) | Соединения, композиции и их применение | |
BR112016023011A2 (pt) | tratamento de câncer gástrico | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
BR112017015597A2 (pt) | moduladores dos receptores da adenosina a3 | |
BR112017007031A2 (pt) | composição farmacêutica para administração subcutânea, método de tratamento de um paciente que sofre de um trauma ou doença de coagulação de sangue, kit de peças, e forma de dosagem de uma composição farmacêutica | |
EA202191014A1 (ru) | Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства | |
BR112015030734A2 (pt) | produto farmacêutico, kit e método de tratamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |